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We collected venous and capillary serum samples from 21 
Zika virus‒infected patients on multiple days after symptom 
onset and found RNA load was higher and median duration 
of virus detection significantly longer in capillary than in ve-
nous blood. These findings raise questions about the role of 
the capillary compartment in virus transmission dynamics.
Zika virus, belonging to the family Flaviviridae and genus Flavivirus, is transmitted to humans by mos-
quito bites but can also be contracted through sexual and 
vertical transmission (1). Zika virus was first detected 
in Brazil in 2015 and has since spread with the same 
speed as chikungunya virus through South and Central 
America and the Caribbean Islands, despite a shorter and 
lower viremia in humans and a longer replication period 
in the vector (2,3). As with other arboviruses, Zika vi-
rus viremia is commonly measured in venous blood, even 
though mosquitoes introduce virus into cutaneous capil-
lary blood. We conducted a prospective descriptive study 
with Zika virus patients during the Zika virus epidemic in 
French Guiana to evaluate the kinetics of Zika virus RNA 
load in serum samples collected sequentially from venous 
and skin capillary blood.
The study population comprised 21 symptomatic and 
consenting Zika virus patients infected during March‒Sep-
tember 2016. We confirmed Zika virus infection by real-
time reverse transcription PCR (RT-PCR) of serum and 
urine samples provided by patients during the first few 
days after symptom onset. We obtained serum samples 
from the venous and cutaneous capillary blood (collected 
from the fingertip) sequentially 1‒18 days after the onset of 
symptoms. The median age of the population was 40 (range 
28–63) years and the sex ratio (male:female) was 1.6. We 
observed no co-morbidities, and all participants were found 
to be free of dengue and chikungunya virus infections by 
methods previously described (4,5).
We extracted RNA from 150-µL samples using the 
QIAamp Viral RNA kit (QIAGEN, Hilden, Germany) 
and performed Zika virus RNA amplification using the 
RealStar Zika Virus RT-PCR Kit 1.0 (Altona Diagnostics 
GmbH, Hamburg, Germany) according to the manufactur-
er’s instructions. We performed Zika virus RNA quantifica-
tion using a reference strain provided by the European Zika 
Virus Archive (SKU no. 001N-01648) and estimated the 
Zika virus RNA load as log10 copies per milliliter (online 
Technical Appendix Table, https://wwwnc.cdc.gov/EID/
article/23/11/17-0337-Techapp1.pdf).
Zika virus RNA loads in capillary blood correlated 
with those in venous blood (Spearman correlation test, 
r = 0.54, p<0.0001) but were significantly higher in the 
capillary samples (Wilcoxon signed rank test, p = 0.0003), 
except for 3 patients (nos. 2, 13, and 21; online Technical 
Appendix Table). The median duration of Zika virus detec-
tion after symptom onset was significantly greater in capil-
lary blood than in venous blood (p = 0.005 by log rank test; 
hazard ratio = 2.99, 95% CI 1.39–6.43), even though the 
duration of detection in capillary blood was underestimat-
ed; RNA was still detectable in the last capillary blood sam-
ples taken from 8 patients (nos. 1, 5, 6, 8, 11, 15, 16, and 
19; online Technical Appendix Table). The duration of Zika 
virus RNA detection was greater in capillary than in venous 
blood for 12 (57%, 95% CI 34%–78%) of the 21 patients 
(nos. 1, 3, 5, 6, 7, 8, 11, 14, 15, 16, 19, and 20). The maxi-
mum duration of RNA detection in capillary blood samples 
was 18 days after the onset of symptoms (seen with patient 
no. 19) with a load of 1.9 log10 copies/mL. The duration 
of detection was equal between the 2 compartments for 7 
(33%, 95% CI 15%–57%) of 21 patients (nos. 4, 9, 10, 12, 
13, 17, and 18) and longer in venous blood for 2 (10%, 95% 
CI 1%–30%) of 21 patients (nos. 2 and 21) (online Techni-
cal Appendix Table).
These data raise questions about the consequences of 
longer persistence and higher loads of Zika virus RNA in 
the cutaneous capillary blood compartment, although we 
did not test Zika virus replication capacity. The higher load 
and longer detection of Zika virus RNA in this compart-
ment might be attributable to Zika virus replication in per-
missive cells of the skin (e.g., human dermal fibroblasts 
and epidermal keratinocytes); capillaries; or both (6). If 
the Zika virus RNA observed in the serum samples taken 
from the capillary compartment reflects the presence of in-
fectious virus particles, symptomatic Zika virus‒infected 
patients would need to be shielded from mosquitoes for a 
longer period than is currently practiced to limit potential 
vectorborne transmission.
This study comparing the kinetics of Zika virus RNA 
load between the venous and capillary compartments 
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highlights the need to further investigate the infectivity and 
pathophysiology of the virus located in the often neglected 
capillary compartment. These findings provide new infor-
mation on this biologic compartment, which plays a key 
role in vectorborne transmission and transmission dynam-
ics. Moreover, these observations, if validated with more 
patients and extended to other vectorborne infections, will 
be vital for preventing and controlling the transmission of 
Zika virus and other arboviruses.
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After conventional molecular and serologic testing failed to 
diagnose the cause of illness, deep sequencing identified 
spotted fever group Rickettsia DNA in a patient’s blood sam-
ple. Sequences belonged to R. honei, the causative agent 
of Flinders Island spotted fever. Next-generation sequenc-
ing is proving to be a useful tool for clinical diagnostics.
When conventional laboratory tests cannot identify an etiologic agent, unbiased deep sequencing performed 
directly on a clinical sample has the potential to identify a 
probable cause of disease. We used deep sequencing to de-
tect spotted fever group (SFG) Rickettsia DNA in the blood 
of a patient for whom diagnosis was not possible through 
conventional molecular and serologic testing.
In late 2016, a middle-aged woman was admitted to a 
regional hospital in Queensland, Australia, after 2 weeks of 
mild cough, myalgia, fever, and lethargy. The day before ad-
mission, she experienced a blanching rash and pains in her 
feet, after which her condition deteriorated and a definite 
petechial rash appeared. Chest radiographs showed atelec-
tasis on 1 side. Meningococcal septicemia was suspected, 
and the patient was transferred to intensive care with septic 
shock. Despite treatment with inotropes and several antimi-
crobial drugs (including ceftriaxone, vancomycin, merope-
nem, doxycycline), the patient died the next morning.
Clinical testing did not identify an infectious dis-
ease agent in the patient’s blood; serologic test results 
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